Genome report: First whole genome sequence of Triatoma sanguisuga (Le Conte, 1855), vector of Chagas disease.

Triatoma sanguisuga is the most widespread triatomine bug species in the United States (US). The species vectors the human parasite Trypanosoma cruzi, which causes Chagas disease. Vector-borne Chagas disease is rarely diagnosed in the US, but T.

Primary gastric T-cell lymphoma presenting with perforation: a case report and review of the literature.

Primary gastric T-cell lymphomas (PGTL) are exceedingly rare with an estimated incidence of 0.0091 per 100,000 person-years, affecting mainly elderly males. PGTL can present with a variety of gastrointestinal symptoms, but patients only rarely present with perforation.

Establishment of a Robot-Assisted Bronchoscopy Program at a Veterans Affairs Hospital.

Lung cancer has high mortality rates attributed to late diagnosis and treatment. Robot-assisted bronchoscopy (RAB) offers promising solutions to these challenges, enabling precise navigation and biopsy of small and difficult-to-reach lung nodules. We present the early outcomes and challenges encountered in establishing an RAB program at a Veterans Affairs (VA) Medical Center.

The Needs and Experiences of Black Families in the Neonatal Intensive Care Unit.

Objectives: To identify opportunities for improvement in quality of care, we explore Black families' experiences of family support in the neonatal intensive care unit (NICU) during their infant's hospital stay.

Methods: Semistructured qualitative interviews or focus groups (FGs) were conducted to explore Black families' experiences of NICU hospitalization. Inclusion criteria were self-identification as a Black family member and infant admission to our NICU between January 2020 and February 2022.

The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron.

Orally bioavailable, synthetic nonpeptide agonists (NPAs) of the glucagon-like peptide-1 receptor (GLP-1R) may offer an effective, scalable pharmacotherapy to address the metabolic disease epidemic. One of the first molecules in the emerging class of GLP-1R NPAs is orforglipron, which is in clinical development for treating type 2 diabetes and obesity. Here, we characterized the pharmacological properties of orforglipron in comparison with peptide-based GLP-1R agonists and other NPAs.